The HTD scheme, which provides 50% funding, aims to stimulate new and innovative health care technologies designed to improve significantly the quality of healthcare in the United Kingdom
Molecular Vision in partnership with Acrongenomics, Pearson Matthews and Imperial College London has been awarded GBP440,000 by the UK Government's Health Technology Devices (HTD) Scheme for the development of a line of low cost, easy-to-use and portable point-of-care diagnostic devices for testing of cardiovascular health.
The HTD scheme, which provides 50% funding, aims to stimulate new and innovative health care technologies designed to improve significantly the quality of healthcare in the United Kingdom.
Molecular Vision's patented diagnostic devices will allow for accurate on-the-spot qualitative and quantitative diagnosis of cardiovascular diseases at first consultation, eliminating the need for patients to make repeat visits and so bringing forward the initiation of treatment, thereby freeing up clinical time, and lowering treatment costs.
The proposed devices have the potential to become a de-facto standard for medical testing and are based on the novel BioLED technology platform, which Molecular Vision is commercializing in partnership with Acrongenomics.
BioLED technology will allow the development of readily portable POC devices for a broad range of medical applications by exploiting two powerful technologies: microfluidics and organic semiconductor devices (light emitting diodes and photodetectors).
Organic polymer light emitting diodes have been the subject of intense scientific and commercial interest since their discovery at Cambridge University in 1989 by Molecular Vision co-founder Professor Donal Bradley - now head of the department of physics at Imperial - and his colleagues.
This early development led Professor Bradley and colleagues to found Cambridge Display Technology.
Commenting on the HTD award, Professor Bradley said, "This is a tremendous step forward for our company.
"This new consortium brings together wide ranging expertise in the development and commercialisation of medical technologies, and will allow us to dramatically accelerate our product development plans."
